PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues – A population pharmacokinetic/pharmacodynamic analysis of rucaparib
Explore this paper's citation graph
Summary
The objectives of this analysis were to establish population PK and PK/PD models for rucaparib, and to evaluate the predictability of PARP action in PBL for PARP activity in tumor tissues.
- Type
- dissertation
- Published
- 2015-03-01
- Cited by
- 5
- References
- 15
- OpenAlex
- https://openalex.org/W27128213
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:36241116
Keywords
Political science
References
- Likelihood based approaches to handling data below the quantification limit using NONMEM VI
- PARP-1 and PARP-2: New players in tumour development.
- Phase I Study Of The Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, In Combination With Temozolomide in Patients with Advanced Solid Tumors
- Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials
- Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery
- Biomarkers in Phase I Oncology Trials: Signal, Noise, or Expensive Distraction?
- Development and Use of Biomarkers in Oncology Drug Development
- PARP as a novel therapeutic target in cancer
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
- Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
- Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.
- Standardized Visual Predictive Check Versus Visual Predictive Check for Model Evaluation
- Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Cited by
- Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients with BRCA 1/2 - Mutated Cancer or PARP Sensitive Tumor Types
- Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases
- Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
- First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
- Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.
Related papers
No related papers recorded.